STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice.
AKT
ERK1/2
STAT5
androgens
cell hierarchy
escape mechanisms
knockout
prolactin
prostate cancer
stem/progenitor cells
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Jul 2019
02 Jul 2019
Historique:
received:
11
06
2019
revised:
28
06
2019
accepted:
28
06
2019
entrez:
5
7
2019
pubmed:
5
7
2019
medline:
5
7
2019
Statut:
epublish
Résumé
The canonical prolactin (PRL) Signal Transducer and Activator of Transcription (STAT) 5 pathway has been suggested to contribute to human prostate tumorigenesis via an autocrine/paracrine mechanism. The probasin (Pb)-PRL transgenic mouse models this mechanism by overexpressing PRL specifically in the prostate epithelium leading to strong STAT5 activation in luminal cells. These mice exhibit hypertrophic prostates harboring various pre-neoplastic lesions that aggravate with age and accumulation of castration-resistant stem/progenitor cells. As STAT5 signaling is largely predominant over other classical PRL-triggered pathways in Pb-PRL prostates, we reasoned that Pb-Cre recombinase-driven genetic deletion of a floxed
Identifiants
pubmed: 31269779
pii: cancers11070929
doi: 10.3390/cancers11070929
pmc: PMC6678910
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Institut National Du Cancer
ID : INCa_6672
Organisme : Institut National de la Santé et de la Recherche Médicale
ID : Recurrent funding
Organisme : Université Paris Descartes
ID : Recurrent funding
Organisme : Centre National de la Recherche Scientifique
ID : Recurrent funding
Organisme : Austrian Science Fund
ID : SFB-F4707 and SFB-F06105
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Lab Invest. 2000 Jul;80(7):993-1006
pubmed: 10908145
Mech Dev. 2001 Mar;101(1-2):61-9
pubmed: 11231059
Int J Cancer. 2001 May 1;92(3):463-5
pubmed: 11291087
Endocrinology. 2001 Jun;142(6):2458-67
pubmed: 11356695
EMBO J. 2001 Dec 3;20(23):6836-44
pubmed: 11726519
Endocrinology. 2002 Jan;143(1):228-38
pubmed: 11751614
Am J Pathol. 2002 Aug;161(2):727-35
pubmed: 12163397
Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62
pubmed: 12209125
J Biol Chem. 2003 Jul 18;278(29):27287-92
pubmed: 12719422
Endocrinology. 2003 Jun;144(6):2269-78
pubmed: 12746285
Endocrinology. 2003 Nov;144(11):4955-66
pubmed: 12960074
Cancer Res. 2003 Dec 15;63(24):8757-62
pubmed: 14695191
Cancer Res. 2004 Mar 15;64(6):2270-305
pubmed: 15026373
Cancer Res. 2004 Jul 15;64(14):4774-82
pubmed: 15256446
Mol Cell Biol. 2004 Sep;24(18):8037-47
pubmed: 15340066
J Biol Chem. 2005 Apr 8;280(14):13817-23
pubmed: 15677474
Clin Cancer Res. 2005 Aug 15;11(16):5863-8
pubmed: 16115927
Endocrinology. 2007 Jul;148(7):3089-101
pubmed: 17412813
Cancer Res. 2008 Jan 1;68(1):236-48
pubmed: 18172316
Clin Cancer Res. 2008 Mar 1;14(5):1317-24
pubmed: 18316550
Endocr Relat Cancer. 2008 Jun;15(2):367-90
pubmed: 18508994
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2610-5
pubmed: 20133806
Endocr Relat Cancer. 2010 May 18;17(2):481-93
pubmed: 20233708
Nat Protoc. 2010 Apr;5(4):702-13
pubmed: 20360765
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Science. 2010 Jul 30;329(5991):568-71
pubmed: 20671189
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15199-204
pubmed: 20699217
Methods Enzymol. 2010;485:583-96
pubmed: 21050937
Mol Cancer Ther. 2011 Feb;10(2):347-59
pubmed: 21216933
Am J Transl Res. 2011 Feb;3(2):133-8
pubmed: 21416055
Eur J Endocrinol. 2011 Aug;165(2):209-15
pubmed: 21602317
Cell Signal. 2011 Nov;23(11):1794-805
pubmed: 21726627
Nat Rev Urol. 2011 Oct 04;8(11):597-607
pubmed: 21971318
Hum Pathol. 2013 Mar;44(3):310-9
pubmed: 23026195
Mol Oncol. 2013 Apr;7(2):190-205
pubmed: 23481269
J Biol Chem. 2013 May 3;288(18):12722-32
pubmed: 23530035
Am J Pathol. 2013 Jun;182(6):2264-75
pubmed: 23660011
Clin Cancer Res. 2013 Oct 15;19(20):5658-74
pubmed: 23942095
Am J Pathol. 2014 Nov;184(11):3105-19
pubmed: 25193592
Prostate. 2015 May;75(7):706-22
pubmed: 25683150
PLoS One. 2015 May 04;10(5):e0125423
pubmed: 25938513
Mol Cancer Ther. 2015 Aug;14(8):1777-93
pubmed: 26026053
Am J Pathol. 2015 Sep;185(9):2505-22
pubmed: 26362718
Oncotarget. 2016 Jul 26;7(30):48093-48106
pubmed: 27344177
Rheumatology (Oxford). 2016 Dec;55(12):2248-2259
pubmed: 27616146
Oncotarget. 2017 Jan 10;8(2):3724-3745
pubmed: 27741508
Cancer Res. 2017 Jan 15;77(2):355-365
pubmed: 27879271
Pharmacol Ther. 2017 Nov;179:111-126
pubmed: 28549597
J Pathol. 2017 Sep;243(1):51-64
pubmed: 28603917
Oncotarget. 2017 Sep 12;8(49):85997-86010
pubmed: 29156772
Leukemia. 2018 May;32(5):1135-1146
pubmed: 29472718
Clin Cancer Res. 2018 Apr 15;24(8):1917-1931
pubmed: 29483142
Nat Rev Urol. 2018 Jul;15(7):453-461
pubmed: 29765146
Front Pharmacol. 2019 Mar 29;10:311
pubmed: 30984003
Prostate. 1987;11(3):229-42
pubmed: 3684783
Prostate. 1994;24(3):162-6
pubmed: 8115281
Genes Dev. 1997 Jan 15;11(2):179-86
pubmed: 9009201
J Clin Invest. 1997 Feb 15;99(4):618-27
pubmed: 9045863
Mol Endocrinol. 1997 Sep;11(10):1449-57
pubmed: 9280060
Endocr Rev. 1998 Jun;19(3):225-68
pubmed: 9626554